Cord blood stem cells and glutathione for children with autism
Tests cord blood stem cells plus glutathione in children with autism.
Plain-language title generated from the registry record
Registry title: Adia Med of Winter Park LLC Autism Spectrum Disorder Research Study
Key facts
- Where
- Green Bay and Winter Park, United StatesSee the 2 sites
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 3 and 12 years old?
Source: NCT07304440, who can take part
Where in United States
- The Lyday CenterGreen Bay, United StatesTaking people
- Adia Med Of Winter ParkWinter Park, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Adia Med of Winter Park LLC
- Trial code
- NCT07304440
- Record updated
- 22 September 2026
- Original description
This 12-month study tests whether AdiaVita (umbilical cord blood-derived stem cells and exosomes) plus glutathione improves autism symptoms more than glutathione alone in children ages 3-12. About 100 children with confirmed autism will be randomly assigned to one of two groups. One group receives monthly IV AdiaVita plus IV glutathione for 3 months. The other group receives IV glutathione plus a saline placebo infusion for 2 months. Both groups also use a topical glutathione spray twice a day at home. Symptoms are tracked with the Autism Treatment Evaluation Checklist (ATEC), completed by a parent and by a therapist or teacher. Safety is monitored at clinic visits through Month 12. Children who first receive glutathione only, may crossover to receive AdiaVita at no extra cost if they stay medically stable and their family agrees. Participation is voluntary. The study fee is $12,000.Read full original descriptionShow less
Adia MED of Winter Park LLC Autism Spectrum Disorder Research Study
This 12-month study tests whether AdiaVita (umbilical cord blood-derived stem cells and exosomes) plus glutathione improves autism symptoms more than glutathione alone in children ages 3-12. About 100 children with confirmed autism will be randomly assigned to one of two groups. One group receives monthly IV AdiaVita plus IV glutathione for 3 months. The other group receives IV glutathione plus a saline placebo infusion for 2 months. Both groups also use a topical glutathione spray twice a day at home. Symptoms are tracked with the Autism Treatment Evaluation Checklist (ATEC), completed by a parent and by a therapist or teacher. Safety is monitored at clinic visits through Month 12. Children who first receive glutathione only, may crossover to receive AdiaVita at no extra cost if they stay medically stable and their family agrees. Participation is voluntary. The study fee is $12,000.
Inclusion: Age 3-12 years; Confirmed ASD diagnosis (DSM-5 criteria, supported by ADOS-2); Parent/guardian willingness to consider experimental treatments and comply with study requirements; Ability to attend all scheduled visits; Able to meet study cost requirements ($12,000 study fee plus bloodwork costs, if applicable) as described in the informed consent.
Exclusion: Prior stem cell or glutathione therapy: History of stem cell therapy (including umbilical cord blood-derived stem cells or exosomes) or glutathione therapy (intravenous or topical) at any time prior to screening; Severe allergies to study products; Significant uncontrolled medical conditions; Pregnancy or breastfeeding (if applicable); Participation in another interventional trial within 30 days.